Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

This trial tests whether adding acalabrutinib — a targeted drug that blocks a protein called BTK involved in blood cancer cell survival — to a gentler version of standard chemotherapy (called R-miniCHOP) can improve outcomes for older or frail adults with a type of aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL). **You may be eligible if...** - You are 60 years or older, OR are younger but have significant health conditions that make standard-intensity chemotherapy too risky - You have been newly diagnosed with DLBCL (a type of fast-growing lymphoma) - You have not yet received treatment for this cancer - Your heart function is adequate (ejection fraction ≥ 50%) **You may NOT be eligible if...** - You have received prior treatment for this lymphoma - You have a serious infection or uncontrolled illness - You have significant heart rhythm problems or take medications that could interact with the study drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.